Role of interleukin-6 in cachexia: Therapeutic Implications

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 4, 2014, Pages 321-327

  Narsale, Aditi A ^a,b   Carson, James A ^a,b,c  

^a Exercise Science Department   (United States)

^b Department of Exercise Science Division of Applied Physiology   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cancer cachexia; Gut; IL 6 therapies; Liver; Skeletal muscle

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; MONOCLONAL ANTIBODY; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ANIMAL; AUTOPHAGY; CACHEXIA; COMPLICATION; HUMAN; LIVER; METABOLISM; MOUSE; MUSCLE ATROPHY; NEOPLASM; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SMALL INTESTINE;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOPHAGY; CACHEXIA; HUMANS; INTERLEUKIN-6; INTESTINE, SMALL; JANUS KINASES; LIVER; MICE; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS; PROTEOLYSIS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84925454325     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000091     Document Type: Review

References (57)

1. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab 2012; 16:153-166.
2. Onesti JK, Guttridge DC. Inflammation based regulation of cancer cachexia. Biomed Res Int 2014; Epub ahead of print.
3. Ando K, Takahashi F, Motojima S, et al. Possible role for tocilizumab, an antiinterleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 2013; 31:e69-e72.
4. Gallagher IJ, Stephens NA, MacDonald AJ, et al. Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies. Clin Cancer Res 2012; 18:2817-2827.
5. Laine A, Iyengar P, Pandita TK. The role of inflammatory pathways in cancerassociated cachexia and radiation resistance. Mol Cancer Res 2013; 11:967-972.
6. Petruzzelli M, Schweiger M, Schreiber R, et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab 2014; 20:433-447.
7. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10:90-99.
8. White JP, Puppa MJ, Narsale A, et al. Characterization of the male ApcMin/R mouse as a hypogonadism model related to cancer cachexia. Biol Open 2013; 2:1346-1353.
9. Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metabol 2012; 303:E410-E421.
10. Suh SY, Choi YS, Yeom CH, et al. Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer. Support Care Cancer 2013; 21:3071-3077.
11. Sommer J, Engelowski E, Baran P, et al. Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis. Int J Mol Med 2014; 34:651-660.
12. Tachibana S, Zhang X, Ito K, et al. Interleukin-6 is required for cell cycle arrest and activation of DNA repair enzymes after partial hepatectomy in mice. Cell Biosci 2014; 4:6.
13. Yang Y, Ju D, Zhang M, et al. Interleukin-6 stimulates lipolysis in porcine adipocytes. Endocrine 2008; 33:261-269.
14. Begue G, Douillard A, Galbes O, et al. Early activation of rat skeletal muscle IL-6/STAT1/STAT3 dependent gene expression in resistance exercise linked to hypertrophy. PLoS One 2013; 8:e57141.
15. Wang K, Grivennikov SI, Karin M. Implications of anticytokine therapy in colorectal cancer and autoimmune diseases. Ann Rheum Dis 2013; 72 (Suppl. 2):ii100-ii103.
16. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014; 26:54-74.
17. Puppa MJ, White JP, Velazquez KT, et al. The effect of exercise on IL-6 induced cachexia in the Apc min/R mouse. J Cachexia Sarcopenia Muscle 2012; 3:117-137.
18. Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front Immunol 2014; 5:58.
19. White UA, Stephens JM. The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr Pharm Des 2011; 17:340- 346.
20. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014; 26:2-12.
21. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: A highly regulated and dynamic system. Cytokine 2014; 70:11-20.
22. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- And anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813: 878-888.
23. Puppa MJ, Murphy EA, Fayad R, et al. Cachectic skeletal muscle response to a novel bout of low-frequency stimulation. J Appl Physiol 2014; 116:1078- 1087.
24. Penna F, Bonelli G, Baccino FM, et al. Chapter Eleven - Mechanism based therapeutic approaches to cachexia. Waltham, Massachusetts: Academic Press; 2013.
25. Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia - pathophysiology and management. J Gastroenterol 2013; 48:574-594.
26. Gordon BS, Kelleher AR, Kimball SR. Regulation of muscle protein synthesis and the effects of catabolic states. Int J Biochem Cell Biol 2013; 45:2147- 2157.
27. White JP, Puppa MJ, Gao S, et al. Muscle mTORC1 suppression by IL-6 during cancer cachexia: A role for AMPK. Am J Physiol Endocrinol Metab 2013; 304:E1042-E1052.
28. Bonetto A, Aydogdu T, Kunzevitzky N, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 2011; 6:e22538.
29. White JP, Baynes JW, Welle SL, et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/R) mouse. PLoS One 2011; 6:e24650.
30. Egerman MA, Glass DJ. Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol 2014; 49:59-68.
31. White JP, Puppa MJ, Sato S, et al. IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the Apc min/R mouse. Skelet Muscle 2012; 2:14.
32. Puppa MJ, Gao S, Narsale AA, et al. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia. FASEB J 2014; 28:998- 1009.
33. Tardif N, Klaude M, Lundell L, et al. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am J Clin Nutr 2013; 98:1485-1492.
34. Stephens NA, Gallagher IJ, Rooyackers O, et al. Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med 2010; 2:1.
35. Williams JP, Phillips BE, Smith K, et al. Effect of tumor burden and subsequent surgical resection on skeletal muscle mass and protein turnover in colorectal cancer patients. Am J Clin Nutr 2012; 96:1064-1070.
36. Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 2012; 31:765-773.
37. Johns N, Hatakeyama S, Stephens NA, et al. Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle. PLoS One 2014; 9:e83618.
38. Ruzzo A, Catalano V, Canestrari E, et al. Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: A background for an alternative target therapy. BMC Cancer 2014; 14:357.
39. Jones A, Friedrich K, Rohm M, et al. TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO Mol Med 2013; 5:294-308.
40. Sumpter TL, Dangi A, Matta BM, et al. Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO. J Immunol 2012; 189:3848-3858.
41. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-1383.
42. Puppa MJ, White JP, Sato S, et al. Gut barrier dysfunction in the Apc min/R mouse model of colon cancer cachexia. Biochim Biophys Acta 2012; 1812: 1601-1606.
43. Mi L, Lin J, Zheng H, et al. Bacterial translocation contributes to cachexia from locally advanced gastric cancer. Hepatogastroenterology 2012; 59:2348- 2351.
44. Bindels LB, Delzenne NM. Muscle wasting: The gut microbiota as a new therapeutic target? Int J Biochem Cell Biol 2013; 45:2186-2190.
45. Bindels LB, Beck R, Schakman O, et al. Restoring specific lactobacilli levels decreases inflammation and muscle atrophy markers in an acute leukemia mouse model. PLoS One 2012; 7:e37971.
46. Srivastava DS, Dhaulakhandi DB. Role of NF-KB in loss of skeletal muscle mass in cancer cachexia and its therapeutic targets. Am J Cancer Biol 2013; 1:8-23.
47. Velazquez KT, Enos RT, Narsale AA, et al. Quercetin supplementation attenuates the progression of cancer cachexia in ApcMin/R mice. J Nutr 2014; 144:868-875.
48. Ulrich CM, Steindorf K, Berger NA, et al. Biological pathways impacting cancer survival: exercise as a countermeasure for the development and progression of cachexia. Exercise, energy balance and cancer. New York: Springer; 2012; pp. 59-81.
49. Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904-910.
50. Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol 2013; 88:625- 636.
51. Wen HS, Li X, Cao YZ, et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy 2012; 58:461-467.
52. Amitani M, Asakawa A, Amitani H, et al. Control of food intake and muscle wasting in cachexia. Int J Biochem Cell Biol 2013; 45:2179-2185.
53. Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle 2014; 5:83-87.
54. Bayliss TJ, Smith JT, Schuster M, et al. A humanized anti-IL-6 antibody (ALD518) in nonsmall cell lung cancer. Expert Opin Biol Ther 2011; 11:1663-1668.
55. Hirata H, Tetsumoto S, Kijima T, et al. Favorable responses to tocilizumab in two patients with cancer-related cachexia. J Pain Symptom Manage 2013; 46:e9-e13.
56. Ando K, Takahashi F, Kato M, et al. Tocilizumab, a proposed therapy for the cachexia of interleukin6-expressing lung cancer. PLoS One 2014; 9: e102436.
57. Berti A, Boccalatte F, Sabbadini MG, et al. Assessment of tocilizumab in the treatment of cancer cachexia. J Clin Oncol 2013; 31:2970.